OTC •
Healthcare •
Biotechnology •
Quote as of 08/25/2026 15:58
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeOTC
Market Capitalization46,750 mln
Float240 mln
Earnings Date02/25/2027
EPS
6.52
Strong
P / E
20.03
Premium valuation
Piotroski F-Score
9
/ 9
Exceptional
Beneish M-Score
-2.49
Borderline
1-Year Forecast
165
Strong upside
Relative Strength
47
/ 100
In line with market
Business Description
UCB SA is a Belgian biopharmaceutical company founded in 1925 and headquartered in Brussels, focused on developing medicines for people living with neurological and immune system conditions. Its portfolio includes established treatments for epilepsy, Parkinson's disease, rheumatoid arthritis, psoriasis, and osteoporosis, among other serious conditions. The company is also advancing a pipeline of new therapies targeting Alzheimer's disease, lupus, and several rare genetic disorders. In addition to its research and commercial activities, UCB provides contract manufacturing services.
